| 2016 |
Gao L, Hu H, Zhao F-L, Li S-C, 'Can the Direct Medical Cost of Chronic Disease Be Transferred across Different Countries? Using Cost-of-Illness Studies on Type 2 Diabetes, Epilepsy and Schizophrenia as Examples', PLOS ONE, 11 (2016) [C1]
|
|
|
| 2015 |
Lang DL, Zhao FL, Robertson J, 'Prevention of postpartum haemorrhage: Cost consequences analysis of misoprostol in low-resource settings', BMC Pregnancy and Childbirth, (2015) [C1]
© 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization... [more] © 2015 Lang et al. Background: While inferior to oxytocin injection in both efficacy and safety, orally administered misoprostol has been included in the World Health Organization Model List of Essential Medicines for use in the prevention of postpartum haemorrhage (PPH) in low-resource settings. This study evaluates the costs and health outcomes of use of oral misoprostol to prevent PPH in settings where injectable uterotonics are not available. Methods: A cost-consequences analysis was conducted from the international health system perspective, using data from a recent Cochrane systematic review and WHO's Mother-Baby Package Costing Spreadsheet in a hypothetical cohort of 1000 births in a mixed hospital (40 % births)/community setting (60 % births). Costs were estimated based on 2012 US dollars. Results: Using oxytocin in the hospital setting and misoprostol in the community setting in a cohort of 1000 births, instead of oxytocin (hospital setting) and no treatment (community setting), 22 cases of PPH could be prevented. Six fewer women would require additional uterotonics and four fewer women a blood transfusion. An additional 130 women would experience shivering and an extra 42 women fever. Oxytocin/misoprostol was found to be cost saving (US$320) compared to oxytocin/no treatment. Conclusions: Our findings confirm that, even though misoprostol is not the optimum choice in the prevention of PPH, misoprostol could be an effective and cost-saving choice where oxytocin is not or cannot be used due to a lack of skilled birth attendants, inadequate transport and storage facilities or where a quality assured oxytocin product is not available. These benefits need to be weighed against the large number of additional side effects such as shivering and fever, which have been described as tolerable and of short duration.
|
|
|
| 2015 |
Gao L, Zhao FL, Li SC, 'Efficacy and Safety of Thrombin-Receptor Antagonist (Atopaxar and Vorapaxar) in Patients with Acute Coronary Syndrome or Coronary Artery Disease-A Meta-Analysis of Randomized Controlled Trials', Value in Health Regional Issues, 6 22-32 (2015)
© 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Background: Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) ... [more] © 2015 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Background: Meta-analysis for the efficacy and safety data of thrombin-receptor antagonist (TRA) based on patients with acute coronary syndrome (ACS) or coronary artery disease (CAD) and indirect comparisons between TRAs were not available. Objectives: We intended to synthesize the primary end points based on different patient populations (ACS or CAD) as well as perform indirect comparison between two newly invented antiplatelet agents atopaxar and vorapaxar. Methods: A literature search was performed in MEDLINE, Embase, and Cochrane Library. Incidences of major adverse cardiovascular events (MACEs) and bleeding events according to thrombolysis in myocardial infarction were selected as primary outcomes, whereas adverse effects were considered as secondary outcomes. Corresponding results were synthesized using Revman 5.1 according to ACS or CAD cohorts. Results: Among the seven included randomized controlled trials, the efficacy end points in the TRA treatment group were favorable compared with placebo. Specifically, the odds ratio (OR) of MACEs was 0.80 (95% confidence interval [CI] 0.52-1.22) for patients with ACS and 0.74 (95% CI 0.53-1.05) for the cohort with CAD. The events of bleeding were unanimously superior in the placebo arm for both cohorts. The indirect comparison showed a superior trend in favor of atopaxar over vorapaxar in occurrences of MACEs (OR 0.93; 95% CI 0.38-1.32), myocardial infarction (OR 0.52; 95% CI 0.13-0.95), and cardiovascular death (OR 0.82; 95% CI 0.12-4.24) and caused less incidence of bleeding. Conclusions: Besides being more effective than placebo in improving the incidence of MACEs but with a higher risk of bleeding, TRAs may exert different effects in patients with ACS and CAD. Indirect comparisons also suggested that atopaxar might be better than vorapaxar in lowering the incidence of MACEs, myocardial infarction, and cardiovascular death and at the same time with lower risks of bleeding.
|
|
|
| 2014 |
Wu J, Han Y, Zhao F-L, Zhou J, Chen Z, Sun H, 'Validation and comparison of EuroQoL-5 dimension (EQ-5D) and Short Form-6 dimension (SF-6D) among stable angina patients', HEALTH AND QUALITY OF LIFE OUTCOMES, 12 (2014)
|
|
|
| 2013 |
Zhao F-L, Xie F, Hu H, Li S-C, 'Transferability of Indirect Cost of Chronic Disease: A Systematic Review and Meta-Analysis', PHARMACOECONOMICS, 31 501-508 (2013)
|
|
|
| 2013 |
Gao L, Xia L, Zhao F-L, Li S-C, 'Clinical efficacy and safety of the newer antiepileptic drugs as adjunctive treatment in adults with refractory partial-onset epilepsy: A meta-analysis of randomized placebo-controlled trials', EPILEPSY RESEARCH, 103 31-44 (2013) [C1]
|
|
|
| 2013 |
Zhao F, Gao L, Li S, 'Burden of Disease Studies in the Asia-Pacific Region: Are There Enough being Performed to Provide Information for Evidence-Based Health Policy?', Value in Health Regional Issues, 2 152-159 (2013) [C1]
|
|
|
| 2012 |
Gao L, Zhao F, Li SC, 'Cost-utility analysis of liraglutide versus glimepiride as add-on to metformin in type 2 diabetes patients in China', International Journal of Technology Assessment in Health Care, 28 436-444 (2012) [C1]
|
|
|
| 2012 |
Gao L, Zhao F, Li SC, 'Statin is a reasonable treatment option for patients with polycystic ovary syndrome: A meta-analysis of randomized controlled trials', Experimental and Clinical Endocrinology and Diabetes, 120 367-375 (2012) [C1]
|
|
|
| 2011 |
Zhao F, Yue M, Yang H, Wang TA, Wu J-H, Li SC, 'Willingness to pay per quality-adjusted life year: Is one threshold enough for decision-making? Results from a study in patients with chronic prostatitis', Medical Care, 49 267-272 (2011) [C1]
|
|
|
| 2010 |
Zhao F, Yue M, Yang H, Wang T, Wu J-H, Li SC, 'Health-related quality of life in Chinese patients with chronic prostatitis/chronic pelvic pain syndrome', Quality of Life Research, 19 1273-1283 (2010) [C1]
|
|
|
| 2006 |
Zhao F-L, Hu J-IH, Zhu X-Z, 'Monocyte-mediated rotenone neurotoxicity towards human neuroblastoma SH-SY5Y: Role of mitogen-activated protein kinases', BIOLOGICAL & PHARMACEUTICAL BULLETIN, 29 1372-1377 (2006)
|
|
|
| 2006 |
Liu DZ, Zhao FL, Liu J, Li XQ, Ye Y, Zhu XZ, 'Potentiation of adenosine A
The effect of paeoniflorin (PF), a major constituent isolated from Paeony radix, on N6-Cyclopentyladenosine (CPA), a selective adenosine A 1 receptor (A1 receptor) agonist, induce... [more] The effect of paeoniflorin (PF), a major constituent isolated from Paeony radix, on N6-Cyclopentyladenosine (CPA), a selective adenosine A 1 receptor (A1 receptor) agonist, induced antinociception was examined in mice. In the tail-pressure test, CPA (0.05, 0.1, 0.2 mg/kg, s.c.) could induce antinociception in a dose-dependent manner. PF (5, 10, 20 mg/kg, s.c.) alone failed to exhibit any antinociceptive effect in mice; however, pretreatment of PF (20 mg/kg, s.c.) could significantly enhance CPA-induced antinociception. Additionally, pretreatment of 8-Cyclopentyl-1,3- dipropylxanthine (DPCPX, 0.25 mg/kg, s.c.), a selective A1 receptor antagonist, could antagonize the antinociceptive effect of combining CPA with PF. Furthermore, in the competitive binding experiments, PF did not displace the binding of [3H]-8-Cyclopentyl-1,3-dipropylxanthine ([ 3H]-DPCPX) but displaced that of [3H]-2-Chloro-N 6-cyclopentyladenosine ([3H]-CCPA, a selective A 1 receptor agonist) to the membrane preparation of rat cerebral cortex. These results suggested that PF might selectively increase the binding and antinociceptive effect of CPA by binding with A1 receptor. © 2006 Pharmaceutical Society of Japan.
|
|
|
| 2005 |
Xiao L, Zhao FL, Zhu XZ, 'Down regulation of cyclooxygenase-2 is involved in delayed neuroprotection by ischemic preconditioning in rats', Acta Pharmacologica Sinica, 26 441-446 (2005)
Aim: To examine whether the prostaglandins (PGs) pathway is involved in triggering delayed neuroprotection by ischemic preconditioning (IPC) and evaluate the effects of IPC on cyc... [more] Aim: To examine whether the prostaglandins (PGs) pathway is involved in triggering delayed neuroprotection by ischemic preconditioning (IPC) and evaluate the effects of IPC on cyclooxygenase-2 (COX-2) expression following focal cerebral ischemia and reperfusion in rats. Methods: IPC was induced by 10 min of saline infusion into the left internal carotid artery with the right common carotid artery clamped at the same time. Middle cerebral artery occlusion (MCAO) and reperfusion model was produced using intraluminal filament method. Results: IPC 48 h prior to MCAO significantly reduced infarct area as compared with MCAO alone. A nonselective inhibitor of COX indomethacin (3 mg/kg ip) applied 1 h prior to or 1 h after IPC failed to affect its protective effects. IPC had no direct effect on the cortex COX-2 mRNA and protein expression 72 h later, but decreased the expression of COX-2 mRNA and protein following ischemia and reperfusion insult. Conclusion: PGs pathways was not involved in triggering delayed neuroprotection by IPC, and IPC induced down-regulation of COX-2 following focal cerebral ischemia and reperfusion in rats in vivo. © 2005 CPS and SIMM.
|
|
|
